CY1121684T1 - Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης - Google Patents
Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνηςInfo
- Publication number
- CY1121684T1 CY1121684T1 CY20191100400T CY191100400T CY1121684T1 CY 1121684 T1 CY1121684 T1 CY 1121684T1 CY 20191100400 T CY20191100400 T CY 20191100400T CY 191100400 T CY191100400 T CY 191100400T CY 1121684 T1 CY1121684 T1 CY 1121684T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compound
- preparation
- diarylthioyadantoine
- intermediates
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000011835 investigation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/14—Phosphorus; Compounds thereof
- B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
- B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
- B01J27/198—Vanadium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/04—Mixing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094436P | 2014-12-19 | 2014-12-19 | |
| PCT/US2015/066356 WO2016100652A2 (en) | 2014-12-19 | 2015-12-17 | Process for the preparation of a diarylthiohydantoin compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121684T1 true CY1121684T1 (el) | 2020-07-31 |
Family
ID=55168400
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100400T CY1121684T1 (el) | 2014-12-19 | 2019-04-10 | Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης |
| CY20201101031T CY1123611T1 (el) | 2014-12-19 | 2020-11-02 | Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης |
| CY20221100408T CY1125243T1 (el) | 2014-12-19 | 2022-06-10 | Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201101031T CY1123611T1 (el) | 2014-12-19 | 2020-11-02 | Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης |
| CY20221100408T CY1125243T1 (el) | 2014-12-19 | 2022-06-10 | Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης |
Country Status (34)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3233803T3 (pl) * | 2014-12-19 | 2019-07-31 | Aragon Pharmaceuticals, Inc. | Sposób wytwarzania związku diarylotiohydantoiny |
| SG10201907094QA (en) * | 2014-12-19 | 2019-09-27 | Aragon Pharmaceuticals Inc | Processes for the preparation of a diarylthiohydantoin compound |
| CN108069869B (zh) * | 2016-11-09 | 2022-03-01 | 上海医药工业研究院 | 一种Apalutamide的制备方法及其中间体 |
| TW201831461A (zh) * | 2017-01-18 | 2018-09-01 | 台灣神隆股份有限公司 | 製備阿帕魯醯胺的方法 |
| US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| CN107501237B (zh) * | 2017-08-17 | 2022-03-22 | 上海西浦医药科技有限公司 | 一种Apalutamide的合成方法 |
| CN108383749B (zh) * | 2018-01-30 | 2021-03-09 | 杭州科巢生物科技有限公司 | 阿帕鲁胺的合成方法及其中间体 |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| CN108314646B (zh) * | 2018-04-11 | 2021-03-19 | 武汉慧敏科技中心 | 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法 |
| CN109651256A (zh) * | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| CN110511207A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
| CN110511206A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
| CN113968815B (zh) * | 2020-07-24 | 2025-11-18 | 苏州科伦药物研究有限公司 | 一种硫代二氮杂螺类化合物的合成方法、其中间体及其合成方法 |
| WO2022049265A1 (en) | 2020-09-04 | 2022-03-10 | Synthon B.V. | Improved process for preparation of apalutamide |
| JP2023550386A (ja) | 2020-11-20 | 2023-12-01 | アムジエン・インコーポレーテツド | ７－クロロ－６－フルオロ－１－（２－イソプロピル－４－メチルピリジン－３－イル）ピリド［２，３－ｄ］ピリミジン－２，４（１Ｈ，３Ｈ）－ジオンを調製するためのプロセス |
| CN113402466B (zh) * | 2021-06-18 | 2022-08-16 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法 |
| CN113292535B (zh) * | 2021-06-18 | 2022-07-01 | 南京方生和医药科技有限公司 | 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法 |
| CN115572264B (zh) * | 2021-07-06 | 2025-12-05 | 山东新时代药业有限公司 | 一种恩杂鲁胺的制备方法 |
| CN115850233B (zh) * | 2021-09-24 | 2024-12-10 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺的合成方法 |
| CN116239536A (zh) * | 2021-12-08 | 2023-06-09 | 山东新时代药业有限公司 | 一种阿帕鲁胺中间体化合物 |
| CN115536634B (zh) * | 2022-10-17 | 2024-06-11 | 上海博悦生物科技有限公司 | 一种阿帕他胺的合成方法 |
| CN116332907A (zh) * | 2023-03-16 | 2023-06-27 | 奥锐特药业股份有限公司 | 一种无定形阿帕他胺的制备方法 |
| CN117645572A (zh) * | 2023-11-23 | 2024-03-05 | 奥锐特药业股份有限公司 | 恩扎卢胺及其中间体的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077605A1 (en) | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| PL3412290T3 (pl) * | 2006-03-27 | 2021-09-06 | The Regents Of The University Of California | Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym |
| WO2008119015A2 (en) * | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| WO2009140624A2 (en) * | 2008-05-16 | 2009-11-19 | Takeda San Diego, Inc. | Glucokinase activators |
| BR112012015868A2 (pt) * | 2009-12-11 | 2017-06-20 | Autifony Therapeutics Ltd | derivados de imidazolidinadiona |
| EA028869B1 (ru) * | 2010-02-16 | 2018-01-31 | Арагон Фармасьютикалс, Инк. | Модуляторы рецептора андрогенов и их применение |
| EP2538785B1 (en) * | 2010-02-24 | 2018-03-21 | Medivation Prostate Therapeutics LLC | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds |
| CA2829322C (en) * | 2011-03-10 | 2017-01-10 | Suzhou Kintor Pharmaceuticals, Inc. | Substituted thioimidazolidinone androgen receptor antagonists and uses thereof |
| WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| AU2013240141B2 (en) * | 2012-03-29 | 2017-11-02 | Sangart, Inc. | Diaspirin crosslinked PEGgylated hemoglobin |
| AU2014273618B2 (en) * | 2013-05-29 | 2016-10-13 | Hinova Pharmaceuticals Inc. | Imidazole diketone compound and use thereof |
| PL3233803T3 (pl) * | 2014-12-19 | 2019-07-31 | Aragon Pharmaceuticals, Inc. | Sposób wytwarzania związku diarylotiohydantoiny |
-
2015
- 2015-12-17 PL PL15823875T patent/PL3233803T3/pl unknown
- 2015-12-17 US US14/973,089 patent/US9688655B2/en active Active
- 2015-12-17 SG SG10201912805SA patent/SG10201912805SA/en unknown
- 2015-12-17 BR BR112017013113-7A patent/BR112017013113B1/pt active IP Right Grant
- 2015-12-17 LT LTEP18169756.6T patent/LT3372584T/lt unknown
- 2015-12-17 PT PT15823875T patent/PT3233803T/pt unknown
- 2015-12-17 WO PCT/US2015/066356 patent/WO2016100652A2/en not_active Ceased
- 2015-12-17 DK DK18169895.2T patent/DK3372585T3/da active
- 2015-12-17 PH PH1/2017/501152A patent/PH12017501152B1/en unknown
- 2015-12-17 ME MEP-2019-86A patent/ME03420B/me unknown
- 2015-12-17 SM SM20190208T patent/SMT201900208T1/it unknown
- 2015-12-17 SM SM20200618T patent/SMT202000618T1/it unknown
- 2015-12-17 RS RS20190350A patent/RS58454B1/sr unknown
- 2015-12-17 EA EA201791390A patent/EA201791390A1/ru unknown
- 2015-12-17 EP EP15823875.8A patent/EP3233803B1/en active Active
- 2015-12-17 HR HRP20190540TT patent/HRP20190540T1/hr unknown
- 2015-12-17 KR KR1020177019551A patent/KR102586059B1/ko active Active
- 2015-12-17 JP JP2017532725A patent/JP6681902B2/ja active Active
- 2015-12-17 CN CN202410667649.2A patent/CN118638097A/zh active Pending
- 2015-12-17 EP EP18169756.6A patent/EP3372584B9/en active Active
- 2015-12-17 MA MA41200A patent/MA41200B1/fr unknown
- 2015-12-17 ES ES15823875T patent/ES2718539T3/es active Active
- 2015-12-17 EA EA201892487A patent/EA201892487A1/ru unknown
- 2015-12-17 NZ NZ732766A patent/NZ732766A/en unknown
- 2015-12-17 PT PT181698952T patent/PT3372585T/pt unknown
- 2015-12-17 EP EP18169895.2A patent/EP3372585B1/en active Active
- 2015-12-17 LT LTEP18169895.2T patent/LT3372585T/lt unknown
- 2015-12-17 TR TR2019/04739T patent/TR201904739T4/tr unknown
- 2015-12-17 UA UAA201707588A patent/UA123201C2/uk unknown
- 2015-12-17 EA EA201892485A patent/EA201892485A1/ru unknown
- 2015-12-17 SG SG10201912802XA patent/SG10201912802XA/en unknown
- 2015-12-17 MX MX2017008179A patent/MX375467B/es active IP Right Grant
- 2015-12-17 RS RS20201378A patent/RS61060B9/sr unknown
- 2015-12-17 SM SM20220242T patent/SMT202200242T1/it unknown
- 2015-12-17 HR HRP20220750TT patent/HRP20220750T1/hr unknown
- 2015-12-17 DK DK18169756.6T patent/DK3372584T5/da active
- 2015-12-17 CN CN201580069602.5A patent/CN107108507B/zh active Active
- 2015-12-17 SI SI201530599T patent/SI3233803T1/sl unknown
- 2015-12-17 CA CA2970937A patent/CA2970937A1/en active Pending
- 2015-12-17 DK DK15823875.8T patent/DK3233803T3/en active
- 2015-12-17 HU HUE18169756A patent/HUE052475T2/hu unknown
- 2015-12-17 ES ES18169895T patent/ES2919951T3/es active Active
- 2015-12-17 IL IL252843A patent/IL252843B2/en unknown
- 2015-12-17 SI SI201531848T patent/SI3372585T1/sl unknown
- 2015-12-17 EP EP18170050.1A patent/EP3372586A1/en not_active Withdrawn
- 2015-12-17 SG SG11201704969QA patent/SG11201704969QA/en unknown
- 2015-12-17 PT PT181697566T patent/PT3372584T/pt unknown
- 2015-12-17 RS RS20220542A patent/RS63455B1/sr unknown
- 2015-12-17 SG SG10201912811QA patent/SG10201912811QA/en unknown
- 2015-12-17 LT LTEP15823875.8T patent/LT3233803T/lt unknown
- 2015-12-17 AU AU2015364537A patent/AU2015364537B2/en active Active
- 2015-12-17 ES ES18169756T patent/ES2827549T3/es active Active
- 2015-12-17 PL PL18169895.2T patent/PL3372585T3/pl unknown
- 2015-12-17 EA EA201892486A patent/EA201892486A1/ru unknown
- 2015-12-17 SI SI201531433T patent/SI3372584T1/sl unknown
- 2015-12-17 MD MDE20170208T patent/MD3233803T2/ro unknown
- 2015-12-17 PL PL18169756T patent/PL3372584T3/pl unknown
- 2015-12-17 HU HUE15823875A patent/HUE042409T2/hu unknown
- 2015-12-18 TW TW108146841A patent/TWI753336B/zh active
- 2015-12-18 TW TW108131622A patent/TWI703132B/zh active
- 2015-12-18 TW TW108131623A patent/TWI689494B/zh active
- 2015-12-18 TW TW104142692A patent/TWI683810B/zh active
- 2015-12-21 AR ARP150104237A patent/AR103228A1/es active IP Right Grant
-
2017
- 2017-07-18 ZA ZA2017/04877A patent/ZA201704877B/en unknown
-
2019
- 2019-04-10 CY CY20191100400T patent/CY1121684T1/el unknown
-
2020
- 2020-03-24 JP JP2020052658A patent/JP6903785B2/ja active Active
- 2020-11-02 CY CY20201101031T patent/CY1123611T1/el unknown
- 2020-11-20 HR HRP20201847TT patent/HRP20201847T2/hr unknown
-
2022
- 2022-06-10 CY CY20221100408T patent/CY1125243T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123611T1 (el) | Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης | |
| CY1121722T1 (el) | Μεθοδοι για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης | |
| CY1126855T1 (el) | Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου | |
| IL269026A (en) | Methods of treating tumor | |
| CY1123581T1 (el) | Νεες μεθοδοι για την παραγωγη ολιγονουκλεοτιδιων | |
| EP3546457A4 (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| EP3558324A4 (en) | CYCLIC STING DINUCLEOTID AGONISTS FOR CANCER TREATMENT | |
| PL3580211T3 (pl) | 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu | |
| LT3455258T (lt) | Odos vėžio gydymo būdai, įvedant pd-1 inhibitorių | |
| IL255261A0 (en) | Methods for treating cancer | |
| IL260443B (en) | Anti-egfr combinations for treating tumors | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| CO2017004516A2 (es) | Anticuerpos anti-ox40 humanizados | |
| HUE052106T2 (hu) | Eljárás rák kezelésére | |
| MX384024B (es) | Peptidos macrociclicos utiles como inmunomoduladores. | |
| HUE050155T2 (hu) | 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére | |
| EP3428643A4 (en) | SUBSTANCE MARKING PLASTER AND METHOD AND DEVICE FOR TISSUE DIAGNOSIS THEREWITH | |
| IL264443A (en) | Methods of treating prostate cancer | |
| EA201692100A1 (ru) | Новые антитела против rnf43 и способы их применения | |
| IL272081A (en) | Photodynamic therapy method for skin disorders | |
| IL265697B1 (en) | Treatment of prostate cancer | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| IL319432A (en) | Methods of treating cancer | |
| IL281600A (en) | Methods of treating cancer |